PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of hsresearchLink to Publisher's site
 
Health Serv Res. 1999 June; 34(2): 525–546.
PMCID: PMC1089022

Prostate cancer treatment and ten-year survival among group/staff HMO and fee-for-service Medicare patients.

Abstract

OBJECTIVE: To compare treatment patterns and the ten-year survival of prostate cancer patients in two large, nonprofit, group/staff HMOs to those of patients receiving care in the fee-for-service health setting. DATA SOURCES/STUDY DESIGN: A cohort of men age 65 and over diagnosed with prostate cancer between 1985 and the end of 1992 and followed through 1994. Subjects (n = 21,741) were ascertained by two population-based tumor registries covering the greater San Francisco-Oakland and Seattle-Puget Sound areas. Linkage of registry data with Medicare claims data and with HMO inpatient utilization data allowed the determination of health plan enrollment and the measurement of comorbid conditions. Multivariate regression models were used to examine HMO versus FFS treatment and survival differences adjusting for sociodemographic and clinical characteristics. PRINCIPAL FINDINGS: Among cases with non-metastatic prostate cancer, HMO patients were more likely than FFS patients to receive aggressive therapy (either prostatectomy or radiation) in San Francisco-Oakland (odds ratio [OR] = 1.69, 95% CI = 1.46-1.96) but not in Seattle (OR = 1.15, 0.93-1.43). Among men receiving aggressive therapy, HMO cases were three to five times more likely to receive radiation therapy than prostatectomy. Overall mortality was equivalent over ten years (HMO versus FFS mortality risk ratio [RR] = 1.01, 0.94-1.08), but prostate cancer mortality was higher for HMO cases than for FFS cases (RR = 1.25, 1.13-1.39). CONCLUSION: Despite marked treatment differences for clinically localized prostate cancer, overall ten-year survival for patients enrolled in two nonprofit group/staff HMOs was equivalent to survival among patients receiving care in the FFS setting, even after adjustment for sociodemographic and clinical characteristics. Similar overall but better prostate cancer-specific survival among FFS patients is most plausibly explained by differences between the HMO and FFS patients in both tumor characteristics and unmeasured patient selection factors.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995 Aug 23;274(8):626–631. [PubMed]
  • Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med. 1993 Apr 29;328(17):1237–1243. [PubMed]
  • Brook RH, Kamberg CJ, McGlynn EA. Health system reform and quality. JAMA. 1996 Aug 14;276(6):476–480. [PubMed]
  • Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. [PubMed]
  • Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, Warner J. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994 Jan 27;330(4):242–248. [PubMed]
  • Clement DG, Retchin SM, Brown RS, Stegall MH. Access and outcomes of elderly patients enrolled in managed care. JAMA. 1994 May 18;271(19):1487–1492. [PubMed]
  • Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992 Jun;45(6):613–619. [PubMed]
  • Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA. 1993 May 26;269(20):2650–2658. [PubMed]
  • Fowler FJ, Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology. 1993 Dec;42(6):622–629. [PubMed]
  • Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995 Jan 25;273(4):289–294. [PubMed]
  • Greenwald HP, Polissar NL, Borgatta EF, McCorkle R. Detecting survival effects of socioeconomic status: problems in the use of aggregate measures. J Clin Epidemiol. 1994 Aug;47(8):903–909. [PubMed]
  • Greenwald HP, Henke CJ. HMO membership, treatment, and mortality risk among prostatic cancer patients. Am J Public Health. 1992 Aug;82(8):1099–1104. [PubMed]
  • Helgesen F, Holmberg L, Johansson JE, Bergström R, Adami HO. Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors. J Natl Cancer Inst. 1996 Sep 4;88(17):1216–1221. [PubMed]
  • Johansson JE, Holmberg L, Johansson S, Bergström R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA. 1997 Feb 12;277(6):467–471. [PubMed]
  • Kassirer JP. The new health care game. N Engl J Med. 1996 Aug 8;335(6):433–433. [PubMed]
  • Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992 May;82(5):703–710. [PubMed]
  • Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999 Jan-Feb;49(1):8–1. [PubMed]
  • Lee-Feldstein A, Anton-Culver H, Feldstein PJ. Treatment differences and other prognostic factors related to breast cancer survival. Delivery systems and medical outcomes. JAMA. 1994 Apr 20;271(15):1163–1168. [PubMed]
  • Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, Brook RH. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995 Jan 11;273(2):129–135. [PubMed]
  • Luft HS, Greenlick MR. The contribution of group- and staff-model HMOs to American medicine. Milbank Q. 1996;74(4):445–467. [PubMed]
  • Manning WG, Leibowitz A, Goldberg GA, Rogers WH, Newhouse JP. A controlled trial of the effect of a prepaid group practice on use of services. N Engl J Med. 1984 Jun 7;310(23):1505–1510. [PubMed]
  • Manton KG, Newcomer R, Lowrimore GR, Vertrees JC, Harrington C. Social/health maintenance organization and fee-for-service health outcomes over time. Health Care Financ Rev. 1993 Winter;15(2):173–202. [PubMed]
  • Mechanic D. Managed care as a target of distrust. JAMA. 1997 Jun 11;277(22):1810–1811. [PubMed]
  • Merrill RM, Brawley OW. Prostate cancer incidence and mortality rates among white and black men. Epidemiology. 1997 Mar;8(2):126–131. [PubMed]
  • Miller RH, Luft HS. Managed care plan performance since 1980. A literature analysis. JAMA. 1994 May 18;271(19):1512–1519. [PubMed]
  • Moon TD, Brawer MK, Wilt TJ. Prostate Intervention Versus Observation Trial (PIVOT): a randomized trial comparing radical prostatectomy with palliative expectant management for treatment of clinically localized prostate cancer. PIVOT Planning Committee. J Natl Cancer Inst Monogr. 1995;(19):69–71. [PubMed]
  • Percy C, Stanek E, 3rd, Gloeckler L. Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health. 1981 Mar;71(3):242–250. [PubMed]
  • Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993 Aug;31(8):732–748. [PubMed]
  • Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995 Feb 15;273(7):548–552. [PubMed]
  • Potosky AL, Merrill RM, Riley GF, Taplin SH, Barlow W, Fireman BH, Ballard-Barbash R. Breast cancer survival and treatment in health maintenance organization and fee-for-service settings. J Natl Cancer Inst. 1997 Nov 19;89(22):1683–1691. [PubMed]
  • Potosky AL, Breen N, Graubard BI, Parsons PE. The association between health care coverage and the use of cancer screening tests. Results from the 1992 National Health Interview Survey. Med Care. 1998 Mar;36(3):257–270. [PubMed]
  • Prorok PC, Connor RJ, Baker SG. Statistical considerations in cancer screening programs. Urol Clin North Am. 1990 Nov;17(4):699–708. [PubMed]
  • Rasell ME. Cost sharing in health insurance--a reexamination. N Engl J Med. 1995 Apr 27;332(17):1164–1168. [PubMed]
  • Retchin SM, Clement DG, Rossiter LF, Brown B, Brown R, Nelson L. How the elderly fare in HMOs: outcomes from the Medicare competition demonstrations. Health Serv Res. 1992 Dec;27(5):651–669. [PMC free article] [PubMed]
  • Retchin SM, Brown RS, Yeh SC, Chu D, Moreno L. Outcomes of stroke patients in Medicare fee for service and managed care. JAMA. 1997 Jul 9;278(2):119–124. [PubMed]
  • Retchin SM, Brown B. The quality of ambulatory care in Medicare health maintenance organizations. Am J Public Health. 1990 Apr;80(4):411–415. [PubMed]
  • Riley GF, Potosky AL, Klabunde CN, Warren JL, Ballard-Barbash R. Stage at diagnosis and treatment patterns among older women with breast cancer: an HMO and fee-for-service comparison. JAMA. 1999 Feb 24;281(8):720–726. [PubMed]
  • Riley G, Tudor C, Chiang YP, Ingber M. Health status of Medicare enrollees in HMOs and fee-for-service in 1994. Health Care Financ Rev. 1996 Summer;17(4):65–76. [PubMed]
  • Riley GF, Potosky AL, Lubitz JD, Brown ML. Stage of cancer at diagnosis for Medicare HMO and fee-for-service enrollees. Am J Public Health. 1994 Oct;84(10):1598–1604. [PubMed]
  • Shaughnessy PW, Schlenker RE, Hittle DF. Home health care outcomes under capitated and fee-for-service payment. Health Care Financ Rev. 1994 Fall;16(1):187–222. [PubMed]
  • Short PF, Lair TJ. Health insurance and health status: implications for financing health care reform. Inquiry. 1994;31(4):425–437. [PubMed]
  • Siu AL, Leibowitz A, Brook RH, Goldman NS, Lurie N, Newhouse JP. Use of the hospital in a randomized trial of prepaid care. JAMA. 1988 Mar 4;259(9):1343–1346. [PubMed]
  • Stuart ME, Handley MA, Thompson RS, Conger M, Timlin D. Clinical practice and new technology: prostate-specific antigen (PSA). HMO Pract. 1992 Dec;6(4):5–11. [PubMed]
  • Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ, Wishnow KI, Kaplan I, Loughlin KR, Richie JP, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol. 1998 Jan;16(1):275–283. [PubMed]
  • Talcott JA, Rieker P, Propert KJ, Clark JA, Wishnow KI, Loughlin KR, Richie JP, Kantoff PW. Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst. 1997 Aug 6;89(15):1117–1123. [PubMed]
  • Ware JE, Jr, Bayliss MS, Rogers WH, Kosinski M, Tarlov AR. Differences in 4-year health outcomes for elderly and poor, chronically ill patients treated in HMO and fee-for-service systems. Results from the Medical Outcomes Study. JAMA. 1996 Oct 2;276(13):1039–1047. [PubMed]
  • Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AG, Jr, Wennberg JE. A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team. Arch Fam Med. 1993 May;2(5):487–493. [PubMed]
  • Whitmore WF., Jr Management of clinically localized prostatic cancer. An unresolved problem. JAMA. 1993 May 26;269(20):2676–2677. [PubMed]

Articles from Health Services Research are provided here courtesy of Health Research & Educational Trust